Further Information - Leica BIOSYSTEMS BOND Mode D'emploi

• Consult Federal, State or local regulations for disposal of any potentially toxic components.
• Minimize microbial contamination of reagents or an increase in non-specific staining may occur.
• Retrieval, incubation times or temperatures other than those specified may give erroneous results. Any such change must be
validated by the user.
Instructions for Use
Wilms' Tumor (WT49) primary antibody was developed for use on the automated BOND system in combination with BOND Polymer
Refine Detection. The recommended staining protocol for Wilms' Tumor (WT49) primary antibody is IHC Protocol F. Heat induced
epitope retrieval is recommended using BOND Epitope Retrieval Solution 2 for 30 minutes.
Results Expected
Normal Tissues
Clone WT49 detected the Wilms' tumor antigen in the nuclei of stromal cells in a number of tissues, decidual cells of the uterus,
granulosa and stromal cells of the ovary, Sertoli cells of the testes and in podocytes and glomeruli of kidney (n=205). Clone WT49 does
not react with endothelial cells.
Tumor Tissues
Clone WT49 stained 4/5 Wilms' tumors, 5/5 malignant mesotheliomas, 6/9 ovarian tumors of various types and 1/3 angiomyolipomas.
No staining was seen in a variety of additional tumors evaluated (n=105). Clone WT49 does not react with desmoplastic small round cell
tumors (DSRCTs).
4
Wilms' Tumor (WT49) is recommended for the detection of the Wilms' tumor protein in normal and tumor tissues
Product Specific Limitations
Wilms' Tumor (WT49) has been optimized at Leica Biosystems for use with BOND Polymer Refine Detection and BOND ancillary
reagents. Users who deviate from recommended test procedures must accept responsibility for interpretation of patient results under
these circumstances. The protocol times may vary, due to variation in tissue fixation and the effectiveness of antigen enhancement, and
must be determined empirically. Negative reagent controls should be used when optimizing retrieval conditions and protocol times.
Troubleshooting
Refer to reference 3 for remedial action.
Contact your local distributor or the regional office of Leica Biosystems to report unusual staining.

Further Information

Further information on immunostaining with BOND reagents, under the headings Principle of the Procedure, Materials Required,
Specimen Preparation, Quality Control, Assay Verification, Interpretation of Staining, Key to Symbols on Labels, and General Limitations
can be found in "Using BOND Reagents" in your BOND user documentation.
Bibliography
1. Clinical Laboratory Improvement Amendments of 1988, Final Rule 57 FR 7163 February 28, 1992.
2. Villanova PA. National Committee for Clinical Laboratory Standards (NCCLS). Protection of laboratory workers from infectious
diseases transmitted by blood and tissue; proposed guideline. 1991; 7(9). Order code M29-P.
3. Bancroft JD and Stevens A. Theory and Practice of Histological Techniques. 4th Edition. Churchill Livingstone, New York. 1996.
4. Omeroglu A and Omeroglu G. Pathologic quiz case: a 13-year-old with multiple abdominal masses. Arch Pathol Lab Med. 2003;
127:e347-e348
ProClin™ 950 is a trademark of Supelco, a part of Sigma-Aldrich Corporation.
Date of Issue
19 October 2018
PA0562
Page 3
4